GIOSTAR CEO and Co-Founder Deven Patel spoke on the most downloaded episode of the “Exploring Leadership” podcast, hosted by military veteran Spence Taylor
GIOSTAR has continuously set the bar for innovation in cancer research. The firm was recently recognized with a prestigious award, given to only 9 other researchers.
Chronic liver disorders (CLDs) affect roughly 844 million people worldwide, and result in the deaths of about two million people each year. GIOSTAR recently conducted research pointing to the potential benefit of stem cell therapy in addressing this epidemic.
Stem cell therapy has applications that extend beyond traditional disorders (i.e., orthopedic injuries), including skin care. In this blog post, we review the potential benefits of stem cells on wrinkles, acne, psoriasis, and other conditions, and clear up common misconceptions.
Are you suffering from neuropathy? Stem cell therapy is showing promise as a solution for neuropathic pain. Learn more here.
Scientific Review: Stem Cells Therapy as a Possible Therapeutic Option in Treating COVID-19 Patients
GIOSTAR leaders recently wrote on the potential benefits of stem cells in combating COVID-19. Published in Stem Cell Reviews and Reports, the review was written by Drs. Anand Srivastava, Prabhat Soni, Diana Esquivel, Rangnath Mishra, Rajasekar Seetharaman, and Anjum Mahmood
GIOSTAR Chairman and Co-Founder Dr. Anand Srivastava recently spoke with Healthcare Weekly about stem cells, COVID-19, and numerous other topics.
Editorial: Mesenchymal stem cells may be a credible alternative therapy to fight with COVID-19 pandemic
Drs. Anand Srivastava and Prabhat Soni write in a medical journal on the potential benefits of stem cells in fighting against COVID-19. GIOSTAR recently received FDA Approval Under Compassionate Use to treat COVID-19 patients under compassionate use.
GIOSTAR Co-Founder Dr. Anand Srivastava discusses his ground-breaking research on creating red blood cells from stem cells. This innovation has the potential to eradicate diseases worldwide by solving three central problems with blood transfusion.